Each week at Seeking Alpha, contributor VFC's Stock House analyzes news items, stocks and stories that made the headlines during the previous trading week, and that may also influence trends during the upcoming week. This week, two ProActive Newsroom companies were covered: Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer and renal disease; and CytoSorbents Corporation (OTCBB: CTSO), a critical care-focused therapeutic device company using blood purification to treat life-threatening illnesses.
For Keryx, VFC's Stock House wrote,
"Shares of both Keryx Biopharmaceuticals and AEterna Zentaris (AEZS), from whom Keryx licensed Perifisone, were both flying higher on Friday in anticipation of trial results that has had shares of these companies on the radars of biotech investors since the beginning of the new year...Already having touched prices this month that are nearly double where the stock opened this year, KERX carries a bit more risk with it than it did while it was trading for under three, but those who are sticking to the long side of the story are confident that positive trial news will carry this one much higher.
The opinions are strong for both sides of the argument, so beware of volatility - and it's not likely that we've seen the end of the headline wars. [It's] worth keeping in mind that positive results don't always equal immediate price spikes...even if the trial news is good, it's possible that we won't have seen the last of the buying opportunities."
For CytoSorbents, VFC's Stock House wrote,
"Ctyosorbents traded over four million shares between last Thursday and Friday, with the large bulk of that number coming on Friday. That's good reason to keep an eye on this stock moving into the coming trading week...Last week's volume spike had shares nearly touching twenty cents again, not an insignificant feat since CTSO has been trading at or below fifteen cents for the better part of the year so far.
Any evidence of gaining sales momentum in Europe or the introduction of a new partner could quickly send shares to the north side of twenty cents again, so take notice of last week's volume."
Read the full article at Seeking Alpha.